BMTRY 781 Methods in Clinical Cancer Research Spring 2019

Instructor: Elizabeth Goodwin Hill, PhD

Professor of Biostatistics

Director, Biostatistics Shared Resource, Hollings Cancer Center

Office: HO 400F

Phone: 843-876-1115

Email: hille@musc.edu

Class hours

General schedule: Tuesday and Thursday 12 – 2pm, March – April 2019 Students should make every effort to attend HCC's Protocol Review Committee at 8am on:

- Friday, March 8th
- Friday, March 29th
- Friday, April 19th

Class will be cancelled either Tuesday or Thursday of the corresponding week to accommodate.

Class location: Education Library, Room 119 (or outside enjoying the weather while we discuss various topics) **Class website**: <u>http://people.musc.edu/~hille/BMTRY781/</u>

Office hours: By appointment

Description: Didactic lectures will cover the following topics:

- "Stat 101" review
- Endpoints vs. objectives
- Phase I trials
 - Algorithmic designs
 - Model-based designs
 - Hybrid designs
 - o Relevant operating characteristics in Phase I
 - First-in-human
 - o Multiple agents
- Phase II trials
 - Futility, efficacy and safety monitoring
 - Simon two-stage designs
 - o Predictive probability designs
 - o Randomized Phase II designs
 - o Phase II with a safety lead-in
 - o "Pick the winner" designs
 - Phase I/II
- Phase III trials
- Additional topics (as time and interest allows)
 - o Basket/Umbrella trials
 - Platform trials
 - o Phase I/III trials and other efforts at 'speeding up' the approval process
 - o Cluster-randomized trials
 - o Pragmatic trials
 - o Feasibility studies
 - Pilot studies
 - PRC/IRB review
 - Informed consent
 - Patient advocacy

<u>Textbooks</u>: No textbook. Reading material (primarily found on the web) will be provided as necessary. This will include journal articles in clinical trial and cancer research journals. Suggested textbooks for reference include:

- Clinical Trials: A Methodologic Perspective (Piantadosi)
- Clinical Trials in Oncology, Third Edition (Green, Benedetti, Smith and Crowley)
- Principles of Anti-Cancer Drug Development (Hidalgo, Eckhardt, Garrett-Mayer, Clendennin)

Prerequisites: eligible students must satisfy at least one of the following criteria:

- (1) The student is a Paul Calabresi K-12 training grant scholar.
- (2) The student is enrolled in a masters or PhD program in the Dept. of Public Health Sciences and instructor permission

Student assessment: P/F – come to class, read the assigned readings, participate in discussions, and you'll be fine.

Course Objectives: At the end of the course, students should be able to:

- (1) Understand the key statistical design components required for designing, activating and implementing a cancer clinical trial.
- (2) Effectively review and critique the statistical design aspects of a clinical trial protocol and published cancer clinical trials research.